ArticleCells2022

An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.

Stefano Cavalieri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.